Nutritional and Physical Exercise Intervention in Older Patients With Malignant Hemopathies

NCT ID: NCT04057443

Last Updated: 2019-08-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-11

Study Completion Date

2023-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical trial to analyze the impact of nutrition and physical exercise intervention program on the completion of treatment in older patients 70 years or older with malignant hemopathology

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVE:

This study aims to determine wether a geriatric intervention based on an individualized program of physical exercise and nutritional support improves the ability to complete oncological treatment at the doses and time initially planned in patients ≥ 70 years affected by hematological malignancies.

DESIGN:

Prospective, clinical trial, randomized, parallel and open groups.

SETTING:

Patients ≥ 70 years recently diagnosed of malignant hematological pathology in a comprehensive cancer center

INTERVENTION:

All those patients who meet the inclusion criteria and agree to participate, will sign the corresponding informed consent and will be assessed through a CGA (comprehensive geriatric assessment), that includes the performance of a physical condition test (SPPB), and randomized to the study group or control group. Patients in the study group will participate in an intervention program with nutritional support and physical exercise during the period in which they are receiving oncological treatment or for a maximum period of 6 months. The patients of the control group will pass to follow up. All patients, regardless of the branch of study to which they are assigned, will receive the oncological treatment indicated by their doctor and a standard follow-up according to the current care protocols in the center.

DETERMINATIONS:

Main variable: proportion of adherence to treatment calculated as the percentage between the dose administered and the prescribed. Adherence over 80% will be considered acceptable.

Secondary variables: geriatric, nutritional and physical-condition parameters before and after the intervention, quality of life before and after the intervention, toxicity and complications during treatment and response to treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematologic Malignancy Old Age; Debility

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

older physical exercise nutrition support hematologic malignancies geriatric assessment geriatric intervention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel design
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention group

Patients in the intervention group will follow the standard treatment and follow-uo according to the clinical protocol of the institution and will participate in an intervention program with physical exercise and nutritional support during the period in which they are receiving oncological treatment or for a maximum period of 6 months.

Group Type EXPERIMENTAL

Nutritional support

Intervention Type OTHER

Nutritional support will be given to all patients according with their nutritional body composition parameters (Nutritional assessment and sarcopenia evaluation). It could be diet counselling, oral supplemented nutrition, enteral nutrition o parenteral nutrition.

Physical exercise

Intervention Type OTHER

The exercise program, designed, applied and monitored by research staff of the Physiology Unit, will have duration of 24 weeks (6 months). The program will have a mixed structure, the participants in an individual way fulfill their training and attend group sessions (8 subjects). In addition, 3 days a week should conduct sessions that will focus on the work of balance and general strength.

Hematologic Drug

Intervention Type DRUG

The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.

Control group

The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.

Group Type ACTIVE_COMPARATOR

Hematologic Drug

Intervention Type DRUG

The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nutritional support

Nutritional support will be given to all patients according with their nutritional body composition parameters (Nutritional assessment and sarcopenia evaluation). It could be diet counselling, oral supplemented nutrition, enteral nutrition o parenteral nutrition.

Intervention Type OTHER

Physical exercise

The exercise program, designed, applied and monitored by research staff of the Physiology Unit, will have duration of 24 weeks (6 months). The program will have a mixed structure, the participants in an individual way fulfill their training and attend group sessions (8 subjects). In addition, 3 days a week should conduct sessions that will focus on the work of balance and general strength.

Intervention Type OTHER

Hematologic Drug

The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* hematological pathology (myelodysplastic syndromes, lymphoproliferative syndromes, multiple myeloma)
* considered able to practice physical exercise
* signed informed consent

Exclusion Criteria

* other hematological pathology
* considered unable to practice physical exercise
Minimum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut d'Investigació Biomèdica de Bellvitge

OTHER

Sponsor Role collaborator

University of Barcelona

OTHER

Sponsor Role collaborator

Instituto de Salud Carlos III

OTHER_GOV

Sponsor Role collaborator

Maite Antonio, MD, Phd

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Maite Antonio, MD, Phd

Coordinator Oncohematogeriatrics Unit. Institut Català d'Oncologia

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maite Antonio, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Institut Català d'Oncologia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institut Català d'Oncologia

L'Hospitalet de Llobregat, Barcelona, Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Maite Antonio, MD, PhD

Role: CONTACT

Phone: +34692083987

Email: [email protected]

Josep Maria Borras, MD,PhD,Prof

Role: CONTACT

Phone: +34932607417

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Maite Antonio, MD,PhD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Ernst M, Wagner C, Oeser A, Messer S, Wender A, Cryns N, Brockelmann PJ, Holtkamp U, Baumann FT, Wiskemann J, Monsef I, Scherer RW, Mishra SI, Skoetz N. Resistance training for fatigue in people with cancer. Cochrane Database Syst Rev. 2024 Nov 28;11(11):CD015518. doi: 10.1002/14651858.CD015518.

Reference Type DERIVED
PMID: 39606939 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PR157/18

Identifier Type: OTHER

Identifier Source: secondary_id

ICOSENIORHEM

Identifier Type: -

Identifier Source: org_study_id